C

Cyfuse Biomedical KK
TSE:4892

Watchlist Manager
Cyfuse Biomedical KK
TSE:4892
Watchlist
Price: 668 JPY 3.09% Market Closed
Market Cap: ¥6.7B

Cyfuse Biomedical KK
Investor Relations

Cyfuse Biomedical KK develops and manufactures cell regenerative systems. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2022-12-01. The firm is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The firm is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The firm is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Ms. Shizuka Akieda
CEO & Director
No Bio Available
Koichi Nakayama M.D., Ph.D.
Co-Founder
No Bio Available
Mr. Masahiro Sanjo
CFO, Head of Corporate Planning & Business Administration and Director
No Bio Available
Mr. Norihiko Tokunaga
GM of System Development Department & Director
No Bio Available

Contacts

Address
TOKYO-TO
Minato-ku
1F, Sumitomo Fudosan Mita Twin Bldg. West, 3-5-27, Mita
Contacts
+81364351885
www.cyfusebio.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett